The global preterm birth control market is expected to reach US$ 1,809.0 Mn in 2025 from US$ 1,190.5 Mn in 2017. The market is estimated to grow with a CAGR of 4.9% from 2018-2025.
The growth of the preterm birth control market is primarily attributed to the increasing investments in R&D by medical devices and pharmaceutical companies. Moreover, increasing number of preterm births across the globe is also expected to drive the growth of preterm birth control market. However, stringent regulatory framework coupled with ethical issues for the clinical trials of pregnant females is expected to obstruct the growth of preterm birth control market. On the other hand, incorporation of Nano-science and nanotechnology, which is one of the leading technologies in modern research is expected to be prevalent future trend in the global preterm birth control market. Application of nano-science and use of nano-materials and nano size components is known as nanotechnology. The technology is used to design new types of "smart" medicines and sensors. It is also used for drug delivery for conditions such as cancer, heart disease, and bacterial infection. According to the Society for Maternal-Fetal Medicine, researchers at the University of Texas Medical School at Houston (UTHealth) are engage in the research regarding the use of nanoparticles to engineer a special drug as most of the drugs used to control preterm birth lead to a number of complications. Liposomal indomethacin known as LIPINDORA, was coated with an oxytocin receptor antagonist in order to make it bind to uterine tissue. This study exhibited positive results and could be used for developing drugs using nanoparticles to prevent preterm birth. Therefore, extensive research in nanotechnology for its application in preterm birth control is one of the key developments in pharmaceutical industry.
Global preterm birth control market, based on the treatment method was segmented into devices and pharmaceutical treatment. In 2017, the pharmaceutical treatment segment held the major market share among the treatment type segment. This is primarily attributed to its ease of use and its increasing recommendation for its use by the healthcare providers as well as its ease of use, and lesser side effects. The pharmaceutical treatment segment is also expected to grow at the fastest rate during the coming years.
Some of the major primary and secondary sources for preterm birth control included in the report are World Health Organization (WHO), Council of Scientific and Industrial Research (CSIR), National Institute for Health and Care Excellence (NICE), Organization for Economic Co-operation and Development (OECD), European Medicines Agency (EMA) and others.